# APRIL (NCT03287804)

> APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03287804
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Autolus Limited
- Conditions: Multiple Myeloma
- Interventions: AUTO2
- Enrollment: 12
- Primary outcome: Phase I - Number of Subjects With Grade 3 to 5 Toxicity During the Dose Limiting Toxicity (DLT) Period
- Primary outcome: Phase I - Number of Subjects With a Dose Limiting Toxicity (DLT)
- Primary outcome: Number of Infused Patients With Best Overall Response

## Indexed commentary on APRIL so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=april-nct03287804